Hepatocellular carcinoma showing tumor stain disappearance with sorafenib treatment and reappearance after treatment reduction and interruption-Reference-Cited by-同舟云学术

Hepatocellular carcinoma showing tumor stain disappearance with sorafenib treatment and reappearance after treatment reduction and interruption

Published:2011 Issue:1 Volume:52 Page:50-55
ISSN:0451-4203
Container-title:Kanzo
language:ja
Short-container-title:Kanzo

Author:

Kawamura Rinako,Seki Toshihito,Ikeda Kozo,Inokuchi Ryosuke,Asayama Toshiki,Yamaguchi Takashi,Tanaka Toshihiro,Yamaguchi Mayu,Miyamoto Sachi,Yoshida Katsunori,Koreeda Chizu,Matsuzaki Kouichi,Okazaki Kazuichi,Fukumoto Takumi,Ku Yonson

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

http://www.jstage.jst.go.jp/article/kanzo/52/1/52_1_50/_pdf

Reference18 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

3. A case of advanced hepatocellular carcinoma who died of metabolic encephalopathy early in the course of treatment with sorafenib with marked changes in imaging findings

4. Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

5. Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in Japan

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A long-term survival case of advanced hepatocellular carcinoma treated with multidisciplinary therapies with progression to hepatic arterial infusion chemotherapy and hepatectomy;Kanzo;2020-08-01

2. A case of hepatocellular carcinoma treated sorafenib therapy showing interesting clinical course about treatment interruption;Kanzo;2012

3. Comparison of tumor response in patients treated with sorafenib for hepatocellular carcinoma;Kanzo;2012

4. Appropriateness and limitations of modified Response Evaluation Criteria in Solid Tumors (mRECIST) in evaluating the efficacy of molecular-targeted therapy for patients with hepatocellular carcinoma;Kanzo;2012